C-2KLQMitoRx Therapeutics
mitochondrial metabolism, small molecule, obesity
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-2KLQ
C-2KLQC-2KLQmitochondrial metabolism, small molecule, obesity
0-100 chain-logic scale · 15 dimensions · scored on public evidence
**We have to apologize for the video quality. Ali's recording corrupted midway through the discussion.** A surgeon-turned-banker who still works the ER and a biotech CEO building what comes after Ozempic, the $13 billion drug class reshaping healthcare, why appetite suppression is a starvation response, and what the next generation looks like. Ali Pashazadeh is the Founder & CEO of Treehill Partners. He still practices emergency medicine. His career spans 30+ years as a trauma surgeon and healthcare investment banker at Goldman Sachs, UBS, and Blackstone. He's seeing GLP-1 side effects in the ER that clinical trials didn't predict. Jon Rees is CEO & Co-founder of MitoRx Therapeutics, developing next-generation obesity treatments that target mitochondria , not appetite. No starvation response. No muscle loss. Timestamps: (00:00) "M&Ms Next to Ozempic" (01:30) Guest Introductions (03:00) Benefits of GLP-1s: $13 Billion Market (06:00) Beyond Weight Loss: Neurological, Renal, Card
MitoRx Therapeutics are developing first-in-class, mitochondrial-targeted sulfide-donor therapies designed to • restore cellular energy • drive fat loss • protect muscle They recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection. At London Life Sciences Week, CEO and fellow Brit Jon Rees gave Onyx the full scoop.
We are pleased to share the recording of the Obesity & Related Conditions Panel: Advanced Therapeutics from the 25th Annual Biotech in Europe Forum (#Sachs_BEF). The engaging session discussed the leaders of modern obesity treatments, MASH and other inflammatory diseases, influence of genetics on obesity and related conditions, and the potential rise in combination treatments for obesity. Co-Chaired by: Elena Startseva, Global Clinical Development Lead, Boehringer Ingelheim International GmbH Victoria English, Co-Founder & Editor, Evernow Publishing Ltd, publisher of MedNous Panellists: Anna Jen Beuchat, Director Business Development, F. Hoffmann-La Roche AG Jackie Iversen, Co-Founder & Chief Clinical Officer, Sen-Jam Pharmaceutical Jon Rees, CEO, MitoRx Therapeutics Jyothis George, CMO, NodThera, Inc. Philip Larsen, CEO, Six Peaks Bio AG
MitoRx’s new obesity drug targets metabolism, not appetite Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search DiamiR, AlzLabs team up to ... Xel … ghlights new GLP-1 care model GARM Clinic debuts world’s first Klotho longevity residency You might also like Scribe lands $25m to advance heart disease gene therapies ŌURA-LillyDirect collab highlights new GLP-1 care model GARM Clinic debuts world’s first Klotho longevity residency NorthStrive eyes emerging GLP-1 opportunity: muscle preservation Stem cell banking partnership targets future of longevity Kyle Umipig Kyle has nine years of editorial writing experience. They hav
MitoRx Therapeutics grabs seed Sign in or Register Sign In / Register Hot Topics Rising Stars AI Secondaries Climate Coverage Emerging Managers Women in Venture Capital Venture Debt Quick Search Rising Stars News & Analysis Cover Stories Friday Letter VCJ 50: The Top 50 Venture Capital Firms in the World LP Perspectives Women of Influence in Private Funds Fundraising Reports Investor Calendar 2026 Magazine Podcasts Firms & Funds VCJ 50: The Top 50 Venture Capital Firms in the World Fundraising Reports Fundraising Stories Emerging Managers Fund Briefs New Partner Profiles People News P … al Firms in the World Fundraising Reports Fundraising Stories Emerging Managers Fund Briefs New Partner Profiles People News People Briefs LPs LP Perspectives Investor Calendar 2026 Meet the LP LP Stories Commitments Allocations Investor Performance Deals & Exits Deal News & Analysis Research & Rankings VCJ 50: The Top 50 Venture Capital Firms in the World Rising Stars Women in Private Funds LIST: Women-led funds LIST: Climate-focused funds LP Perspectives Fundr
MitoRx Therapeutics appoints CSO | MedNous Skip to main content 27 June 2026 Last updated: Thursday 25 June 2026 User account anon menu Login Register and subscribe Search Home News News Appointments Events About MedNous Who We Are Editorial Board Editorial Policy Research Directory Research Directory Organisations Interviewees Terms Topics Contact Us Contact Form Menu Breadcrumb Home MitoRx Therapeutics Appoints CSO MitoRx Therapeutics appoints CSO Thursday 8 May 2025 Company MitoRx Therapeutics Ltd Appointee name Xavier Jacq Country United Kingdom MitoRx Therapeutics Ltd, a developer of mito
Alzheimer's disease(Mitorx Therapeutics) - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Alzheimer's disease(Mitorx Therapeutics) Last update 08 May 2025 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms - Target - Action - Mechanism - Therapeutic Areas Nervous System Diseases Active Indication Alzheimer Disease Inactive Indication - Originator Organization Mitorx Therapeutics Ltd. A … rms with the University, and Ellington, Diaz and d'Oelsnitz have filed a patent application on materials described in this text. Diaz and d'Oelsnitz are each involved with startups related to this research. 13 Oct 2023 · www.fiercebiotech.com 'The Top Line': Unraveling Alzheimer's disease treatments and a look ahead None In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field … responding author of the paper. "That means the results of those studies do not apply to everyone, and this entire group is left out from having the potential benefit of a treatment." Intellectual disability is characterized by an IQ of about 70 or lower. It affects 1.8 -- 3.2% of people worldwide and can occur with conditions such as fragile X syndrome, autism and Down syndrome. Intellectual disability also presents with adaptive behavior challenges. It affects academic achi
MitoRx's next-gen obesity treatment lands £5.5M. InvenireX closes £2M for DNA-based disease detection. Major Crick-Flagship alliance established to boost translation. Subscribe Sign in MitoRx's next-gen obesity treatment lands £5.5M. InvenireX closes £2M for DNA-based disease detection. Major Crick-Flagship alliance established to boost translation. #052 | 24 November 2025 Emily Brown and Andrea Martos Esteban Nov 24, 2025 1 Share This is Cambridge Biocapital’s newsletter the independent weekly bulletin covering business, funding and science news in the world-leading 🇬🇧British 🧬biotech … funding for its pop-up cardboard inhaler, aiming for a Marketing Authorisation Application in 2027 . Rounding out the seed money, Newcastle’s InvenireX raised £2 million for its DNA nanotechnology platform, while London’s Planet Smart raised $1 million pre-seed to replace fossil-based plastics. Those holding the purse strings were also busy: the British Business Bank has committed €30 million to Sofinnova Partners ’ massive €650 million Capital XI fund, reinforcing the UK’s … aneously, the Francis Crick Institute has partnered with Flagship Pioneering to apply its platform-company model to the Crick ’s research. The Oxford–Harrington Rare Disease Centre has named ten 2025 Scholars , each receiving $100k/£100k , with eligibility to advance RNA and cell therapies. On the policy and public purse front, the UK Government announced over £74 million in public–industry investment ( £54 million government grants + £20 million from industry) for eight R&am … LTZ receiving a $50 million upfront payment. GSK also allocated £45 million to fund six Grand Challenge research programmes to combat AMR by early 2026 . Nxera Pharma (R&D in Cambridge) is restructuring to save approximately JPY3.5 billion in UK R&D expenditure in FY2026, targeting savings of at least JPY1.0 billion year-on-year from FY2026. Separately, Advanz Pharma and Alvotech secured EC marketing authorisation for Gobivaz® , a biosimilar to Simponi® . The week’s … led by Lunar Ventures , with additional participation from the Labcorp Venture Fund , Tiny VC, BlueLion Global , Alumni Ventures , and a network of high-profile angels, including Amar Shah , Vivek Garipalli , and Harpreet Rai . Emm has also received non-dilutive funding, including grants that support innovation in women’s health technology. Emm
Alexander Fink - Non Executive Director at MitoRx Therapeutics | The Org Platform Enrich Pricing Log in Sign up MitoRx Therapeutics Alexander Fink Unverified Alexander Fink Non Executive Director Contact Alexander Fink has had a varied career, beginning in 2018 as an Investor at Curve and a Principal at the Fink Family Office, where they worked closely with their father Lord Stanley Fink. In 2019, they were appointed Executive Director at Project Etopia, and in 2020 they became an Investor at Istidama Limited, an Advisor to the Board at Wise Analytics Group, and a Director at Seneca Learning
MitoRx Therapeutics raises £5.5M for obesity treatment | Jon R. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Li
MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimed … s." Oliver Sexton , Investment Director at the UK Innovation & Science Seed Fund, said, "We're delighted to be supporting MitoRx Therapeutics' journey in creating innovative therapeutics for degenerative diseases. The company's platform for reversing mitochondrial dysfunction has great potential to benefit people suffering from both rare and common forms of degenerative disease. " Professor Hideo Kimura , of Sanyo-Onoda City University, Japan , who is considered the … ed by a broad range of investors including the UK Innovation & Science Seed Fund, Wren Capital, Longevitytech.fund, The Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, as well as angel investors. The seed financing will be used to fund pre-clinical proof-of-concept platform development and explore research collaborations and partnerships. References (1) January 2021 - Mitochondrial hydrogen sulfide supplementation improves healt … from a broad range of investors including the UK Innovation & Science Seed Fund, Wren Capital, Longevitytech.fund, The Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, as well as angel investors. For more information visit our website at www.mitorxtherapeutics.com and follow us on LinkedIn . About UK Innovation & Science Seed Fund (UKI2S) UKI2S is a national seed investment fund that nurtures innovative businesses from grea … inesses from great UK science to leverage private investment and grow jobs. The Fund is backed by UKRI, Dstl and other public bodies and is independently managed by specialist venture capital firm Midven, part of Future Planet Capital , the impact-led, global venture capital firm built to invest in high growth potential companies from
MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
RS Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 26 Feb 2026 RS Biotherapeutics, Inc. Startups | Holding Company | 2021 | Maryland, United States | < 10 | rsbiotherapeutics.com Startups | Holding Company | 2021 | Maryland, United States | < 10 | rsbiotherapeutics.com Last update 26 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Respiratory Diseases Infectious Diseases Digestive System Disorders Small molecule drug Di … u moved to the National Institutes of Health as an Intramural Research Training Award (IRTA) Fellow. He subsequently went on to GlaxoSmithKline PLC as a Principal Scientist. During this period, he also completed an MBA at Villanova University. Dr. Hu then established the Small Animal Imaging Program at the Medical College of Georgia. During his most recent position as a Project Officer for the past 14+ years, Dr. Hu was responsible for oversight of technical progress for the … lobal license for RSBT-001 and is projecting filing an Investigational New Drug Application for RSBT-001 and initiating human trials in 2026. More information on RS BioTherapeutics can be found at www.rsbiotherapeutics.com. Media Contact: David Gutierrez, Dresner Corporate Services for RS BioTherapeutics, (312) 780-7204, [email protected] Executive Change 30 Apr 2024 · www.globenewswire.com RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine CUMBERLAN … lobal license for RSBT-001 and is projecting filing an Investigational New Drug Application for RSBT-001 and initiating human trials in 2026. More information on RS BioTherapeutics can be found at www.rsbiotherapeutics.com. Media Contact: David Gutierrez, Dresner Corporate Services for RS BioTherapeutics, (312) 780-7204, [email protected] License out/in 100 Deals associated with RS Biotherapeutics, Inc. Login to view more data 100 Translational Medicine associated with … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
MitoRx Therapeutics | Valuation, Funding Rounds & Stock Price | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Companies MitoRx Therapeutics MitoRx Therapeutics Private Oxford Healthcare & Life Sciences https://mitorxtherapeutics.com Last Round pre-Series A Nov 17, 2025 Momentum Score 50 /100 Company Overview MitoRx Therapeutics is a biotechnology company developing a new category of innovative small molecule mitochondrial metabolic modulators for weight loss with muscle protection in obesity-related indi … investment history Investor Rounds Oshen Holdings SA pre-Series A Longevitytech.fund Seed UK Innovation & Science Seed Fund Seed Wren Capital Seed View all Investors Market signals Structured signals derived from secondary market and firmographic data. Jun 1, 2026 Presenting data at the American Diabetes Association 2026 conference in June. May 17, 2026 Monthly visitors increased 432% MoM. View all signals MitoRx Therapeutics Filings SEC and related filings with document
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth | Markets Insider Business Insider My Markets Watchlist Markets News Search Business Strategy Economy Finance Retail Advertising Careers Law Media Real Estate Small Business The Better Work Project Personal Finance Tech Science AI Enterprise Transportation Startups Innovation Markets Stocks Indices Commodities Crypto Currencies ETFs Lifestyle Entertainment Culture Travel Food Health Education Parenting Military & Defense Politics Reviews Home Kitchen Style Streaming Pets Tech
MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Golf Tennis NFL … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,096.30 +48.70 +1.20% ADVERTIS … 4m seed financing from investors including the UK Innovation & Science Seed Fund, Wren Capital, Longevitytech.fund, the Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, as well as angel investors. For more information visit our website at www.mitorxtherapeutics.com and follow us on LinkedIn . MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts · globe_newswire_uk_374 Terms and Priva
%PDF-1.6 %���� 4087 0 obj > endobj 4105 0 obj >/Filter/FlateDecode/ID[ ]/Index[4087 26]/Info 4086 0 R/Length 96/Prev 707461/Root 4088 0 R/Size 4113/Type/XRef/W[1 3 1]>>stream h�bbd```b``�� �@$� �dQ�LY ��5��f��ٚ`��`��`��`v$�-�u�+$�; ��c3#�.F���OL� A� 3 endstream endobj startxref 0 %%EOF 4112 0 obj >stream hToHSQ?�m�)�ܧìL���C�KW�Y �P���L�- c*(�T�A���CR��B�hZI�?�Q�ǒ���)J��d�B����{�w~��9��s �>��5�� x�/ 9 �v�R! % e2��z��� >/Metadata 189 0 R/Outlines 236 0 R/PageLayout/OneColumn/Pages 4073 0 R/StructTreeRoot 261 0 R/Type/Catalog>> endobj 4089 0 obj >>>/Rotate 0/StructPare … e8c4d59-4e7d-4c39-877c-81559adb104e uuid:7bd93545-974d-4d80-9791-f6a20b3dae63 6 application/pdf Shannon A. Merillat Adobe PDF Library 26.1.59 American Academy of Neurology 0x010100248928C9E49AEC489D2063A947D4B7F1 f15e6914-de12-4161-826a-9524206d080e 244 MediaServiceImageTags true 2025-04-16T17:41:04Z Standard Général 06e1fe28-5f8b-4075-bf6c-ae24be1a7992 fb8235b0-cfa5-458a-92b4-573c8812a53d 0 50, 3, 0, 1 endstream endobj 190 0 obj >stream hޜ�1O1 ������N�8RՅ����C%N�-��K��
MTRX31 Shows Promising Results in Treating High-Risk Obesity | MitoRx Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
Update from... - Graves' Disease and Thyroid Foundation Facebook Log In Graves' Disease and Thyroid Foundation's Post Graves' Disease and Thyroid Foundation August 26, 2025 · Shared with Public Update from Acella Pharmaceuticals (link in comments): All reactions: 13 3 comments Like Comment Most relevant Author Graves' Disease and Thyroid Foundation Link: https://npthyroid.com/faq/product-updates/ NPTHYROID.COM Important Product Updates | NP Thyroid® (thyroid tablets, USP) Important Product Updates | NP Thyroid® (thyroid tablets, USP) 43w 1 Nicole Nagy That's amazi
MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
MitoRx Therapeutics Strengthens Leadership Team with --> Accessibility: Skip TopNav MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth June 09, 2026 07:00 ET | Source: MitoRx Therapeutics Limited MitoRx Therapeutics Limited Alison Strutt appointed as Chief Financial Officer, László Tank ó appointed as Consultant Chief Medical Officer, and Sam Fazeli appointed Non-Executive Director Appointments support MitoRx’s next phase of growth as the Company advances MTRX31 for metabolically unhealthy obesity Harwell Oxford, UK – 9 Ju
There is growing concern surrounding GLP-1 agonists like Ozempic and their potential impact on bone and muscle health. | Norman Law LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continu
PULSE: Empowering the future of UK biotech | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for early-stage entrepreneurs Search … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources PULSE: Empowering the future of UK biotech New alumni case studies added for 2025! Foreword … other companies or building research collaborations with other teams to secure grant funding and deliver important proof of concept data. Coming from a scientific background, it’s easy to assume that the technical side of the business will be straightforward. However, it’s important to stay focused on the commercial aspects of the technology in order to build a successful business, and not be distracted by research activities that won’t directly lead … aling £2.6 million. That includes two Biomedical Catalyst grants, a Smart grant, and a Woman in Innovation award. In 2021, we raised £700,000 in pre-seed investment, led by Venrex, and in 2024, we closed an ASA round with participation from Evenlode Investment, Kayan Ventures, and some notable angels. We’ve also been recognised
MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions Back to A
MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,096.30 +48.70 +1.20% ADVERTIS
The best news in biotech, November 17 - 23 LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cooki … pipeline of ADCs. On the VC front, Sofinnova Partners also announced its newest fund, worth $750M. In terms of dealmaking, we tracked 14 collaborations and partnerships as well as 5 M&A events, with Johnson & Johnson $3B acquisition of Halda Therapeutics the biggest deal of the week. In the clinic we saw 18 positive updates, as well as 10 new drugs approvals in what was a busy week for regulatory announcements. Enjoy! 🚀🧬 New Biotech Launches & Private Raises… So … , a biotech based in TX, USA and led by CEO Michael Torres raised a $15 million grant award from the Cancer Prevention & Research Institute of Texas (CPRIT). The company develops dual-payload ADCs using a branched tripeptide linker platform, and its lead candidate CBB-120 (a TROP-2 targeted TOP1i/ATRi dual-payload ADC) will use the funds for GLP toxicology, manufacturing scale-up and IND filing preparation in 2026. Link MitoRx Therapeutics , a biotech based in the UK and … a biotech based in MA, USA and led by CEO Spring Behrouz received a $5 million grant from the Michael J. Fox Foundation. The company develops small-molecule USP30 inhibitors to restore mitochondrial quality control for Parkinson’s disease. Funds will support IND-enabling studies and biomarker work. Link ReviR Therapeutics , a biotech based in CA, USA and led by CEO Peng Yue received a $4.6 million CIRM grant . The company’s VoyageR™ RNA-modulator platform targets HTT and PMS … ticals , a biotech based in MD, USA and led by CEO Min Li received a $5 million grant from the The Michael J. Fox Foundation for Parkinson's Research . The company is advancing SNP614, a novel antisense oligonucleotide targeting LRRK2 for Parkinson’s disease. Funds will accelerate IND-enabling development. Link Imbria Pharmaceuticals , a biotech
BioM and Sofinnova Partners on Munich's biotech boom | WuXi AppTec posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre … , Altagenics Launch; Cos. Raise Millions; Kernal Biologics Awarded $48M ARPA-H Grant #healthcare #biotech #lifescience #HealthTech #AI 1 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in BYTE51data 1,710 followers 8mo Report this post Expedition Therapeutics , a San Francisco, CA–based biotechnology company, has raised $165 million in Series A financing led by Sofinnova Investments and Novo Holdings , with participation from Forbion , Dawn Biophar
2019 Annual Meeting | S25 - Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes American Academy of Neurology: Neurology Resources | AAN AAN Publications Explore the latest content from across our publications AAN Publications Donate To Research Join The AAN Log In Education Education Education Online Learning Center CME Opportunities NeuroTracker Leadership Programs Education Awards & Scholarships Podcasts Discover learning and leadership opportunities, earn CME, and track credits. See All Research Research Research Abstracts Publications Awards Research Programs & Grant … ams & Grants Donate to Research Explore prestigious scientific journals and award and funding opportunities to advance your research. See All Practice Practice Practice Guidelines Quality Measures Billing & Coding Telehealth Operations Medicare Fee-for-service Benchmarking Clinical Informatics Quality Payment Program Team-based Care Practice Care Models Access practice-improvement tools, including guidelines, measures, and practice management resources. See All Member … The institution of Dr. Darras has received research support from Slaney Family Fund for SMA. The institution of Dr. Darras has received research support from Spinal Muscular Atrophy Foundation. The institution of Dr. Darras has received research support from CureSMA. The institution of Dr. Darras has received research support from Working on Walking Fund . The institution of Dr. Darras has received research support from CHERISH, CS2/CS12 . The institution of Dr. Darras has r
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
All MitoRx Therapeutics Limited (MitoRx) articles | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Business Webinars W
GtR Home About this system Release history Contact us 📣 Help Shape the Future of UKRI's Gateway to Research (GtR) We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email [email protected] . External Collaboration, Innovation and Entrepreneurism: Translational Medicine in Exeter (EXCITEME) Lead Research Organisation: UNIVERSITY OF EXETER Department Nam … research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details. Technical Summary The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and indu … h and Medical Research Council - Development of new therapies for COPD, Project Grant Amount $886,503 (AUD) Organisation National Health and Medical Research Council Sector Public Country Australia Start Description Deciphering the molecular mechanism of Wnt trafficking in gastric cancer Amount £546,665 (GBP) Funding ID MR/S007970/1 Organisation Medical Research Council (MRC) Sector Public Country United Kingdom Start 03/2019 End 03/2022 … ion injury in human donation after cardiac death renal transplantation, Project Grant Amount $162,500 (CAD) Organisation PSI Foundation Sector Academic/University Country Canada Start 03/2018 End 03/2020 Description External Collaboration, Innovation and Entrepreneurism: Translational Medicine in Exeter 2 (EXCITEME2) Amount £24,445 (GBP) Funding ID MC_PC_17189 Organisation Medical Research Council (MRC) Sector Public Country United Kingdom Start … art Description Harnessing academic innovation for the industrial application of CRISPR-Cas technology in the zebrafish, (Winter). Amount £27,000 (GBP) Organisation The Royal Society Sector Charity/Non Profit Country United Kingdom Start 03/2020 End 06/2021 Description ISSF Seed Corn funding Amount £8,550 (GBP) Or
Lubor Gaal Discusses Bio/Pharma M&A Trends at JPM 2026 | MitoRx Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … Is the European Biotech Act the answer to Europe’s innovation gap? The EU’s new proposal aims to strengthen the biotech sector with targeted investment and regulatory reform. Adrián Crespo Velasco examines a key feature: a 12-month extension to Supplementary Protection Certificates for certain novel biotech medicines. The extension is designed to reward innovation, but only for products meeting strict criteria, such as a new active substance and manufacturing steps in the EU.
MitoRx Welcomes New Executives | Jon R. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement
#ada2026 #sachs2026 #biotech #mitorx #obesity #weightloss #drugdevelopment #therapeutics #metabolism #mitochondria | MitoRx Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Co
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
JPM Presentation Tracker – RESI Conference Skip to content Search for: Partnering Session RESI San Diego Investor Panels RESI San Diego Workshops Pitch Pitch Challenge Presenting Companies Pitch Judges Attendees Investors – RESI San Diego 2026 Exhibition Sponsors Contact Us Past RESIs Program Guides Photo Albums Registration RESI San Diego (June) RESI Boston (Sept) Search for: Partnering Session RESI San Diego Investor Panels RESI San Diego Workshops Pitch Pitch Challenge Presenting Companies Pitch Judges Attendees Investors – RESI San Diego 2026 Exhibition Sponsors Contact Us Past RESIs … ic Fibrosis Foundation 1/16/2025 10:00 am 2025 Annual Partnering Forum – FUND: Emerging Funding Sources for Seed-Stage Startups—Crowd Funding, Family Offices, and Foundations RedCrow 1/16/2025 10:00 am 2025 Annual Partnering Forum – FUND: Emerging Funding Sources for Seed-Stage Startups—Crowd Funding, Family Offices, and Foundations Venable LLP 1/16/2025 10:00 am 2025 Annual Partnering Forum – FUND: Emerging Funding Sources for Seed-Stage Startups—Crowd F
Governance Structure :: Oxford BioDynamics PLC (OBD) --> Skip to main content Skip to section navigation Skip to footer Store Careers Contact Us Search Search Search Assets Home About Us Overview Historical Timeline Leadership Team Board of Directors Advisory Panel Products & Services Overview EpiSwitch CiRT EpiSwitch PSE EpiSwitch ME/CFS EpiSwitch Orion EpiSwitch Explorer Specimen Submission Kit OBD Store EpiSwitch® Platform Media Center In the News In the Loop Regulatory News Publications Investors Overview News & Events Company Info Financial Results Stock Data AIM Rule 26 Governanc … g at MTI Ventures LLP, Director, Life Sciences at the Cambridge University Seed Fund and July 2021, Senior Independent Director at Worldwide Healthcare Trust plc. David was appointed to the OBD Board in April 2019. He chairs the Remuneration Committee and is a member of the Audit and Nomination Committees. Member Audit Committee Terms of Reference Download The Remuneration Committee is responsible for determining and agreeing with the Board the framework for the remuneration … g at MTI Ventures LLP, Director, Life Sciences at the Cambridge University Seed Fund and July 2021, Senior Independent Director at Worldwide Healthcare Trust plc. David was appointed to the OBD Board in April 2019. He chairs the Remuneration Committee and is a member of the Audit and Nomination Committees. Chair Peter Presland LL.B, ACA Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of that at the highes … g at MTI Ventures LLP, Director, Life Sciences at the Cambridge University Seed Fund and July 2021, Senior Independent Director at Worldwide Healthcare Trust plc. David was appointed to the OBD Board in April 2019. He chairs the Remuneration Committee and is a member of the Audit and Nomination Committees. Member Peter Presland LL.B, ACA Peter Presland is an experienced Non-Executive Director and Chairman with 50 years' experience in business, much of that at the highe … g at MTI Ventures LLP, Director, Life Sciences at the Cambridge University Seed Fund and July 2021, Senior Independent Director at Worldwide Healthcare Trust plc. David was appointed to the OBD Board in April 2019. He chairs the Remuneration Committee and is a member of the Audit and Nomination Committees. Dr. David Holbrook MA, MB BS, MBA David
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
The Fourth Edition of the Longevity Investors Conference, Held in Gstaad (Switzerland), Unites Visionary Scientists, Industry Titans and Investors for Unprecedented Collaboration Cookie Settings We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use . Necessary Analytics Accept All Accept Selection Reject All × Skip to main content Newsfile Search English Français Deutsch Español Search × Login Username Password Login Newsfile Login Search Français Home About About Company Overview Who We Serve Upcoming Events Career … esearch on Ageing), Bryan Johnson (Founder/CEO of Blueprint and Kernel & OS Fund), Aubrey de Grey (Chief Science Offices, SENS Research Foundation), Brian Kennedy (Director, Centre for Healthy Longevity and Professor Departments of Biochemistry and Physiology, National University of Singapore), Andrew Steele (Scientist and author of Ageless: the New Science of Getting Older Without Getting Old), Greg Bailey (Serial entrepreneur, founder and financier of biotech companies) … n for the luminaries in attendance. The evening featured the 'Maximon Longevity Prize' Award Ceremony. Elisabeth Roider, Partner and Chief Scientific and Medical Officer at Maximon and Tobias Reichmuth, Founding Partner at Maximon, presented the three Prize runner ups: The first prize - Maximon 50k CHF, went to Maurice Michel's research project which aims to extend healthspan and counteract inflammaging by targeting the artificial enzyme function of OGG1 as a therapeutic appr … enzyme function of OGG1 as a therapeutic approach to enhance DNA repair. Second prize, Biolytica's personalized longevity program, went to Dr. Philip Atherton, from the University of Nottingham, who is focused on examining the impact of mTOR inhibition on muscle biology and immune cell function. The project of Dr. Jorge Sanz-Ros and Consuelo Borrá, from the University of Valencia, aims to promote healthy aging using stem cell-derived extracellular vesicles (EVs) and was … g stem cell-derived extracellular vesicles (EVs) and was awarded with the third prize, Avea Life's supplement subscription. The Gala Dinner on the last day of the conference gave the perfect ending to the productive two days, featuring the Maximon Logevity Prize Award Ceremony. To view an enhanced version of this graphic, please visit: https://im
ELRIG unveils keynote speakers for Drug Discovery 2026 | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for early-stage entrepre … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources ELRIG unveils keynote speakers for Drug Discovery 2026 Member news 2 June 2026 ELRIG unveil … on and Torbay CCG. She was a National Advisory Council Member of the King's Fund and a Non-Executive Director of Assura, and is currently a Non Executive Director at Nuffield Health and York Health Economics Consortium. Dr Barrell was awarded a CBE in 2014 for services to healthcare. Dr Saleha Patel will lead the keynote discussion on “20 Years of Discovery: Lessons from the Past, Blueprints for the Next 20” alongside a panel of leaders representing the ecosys … ed inflammatory diseases. Previously he was CEO of life science venture builder fund, Start Codon and epigenomic biomarker discovery pioneer, Cambridge Epigenetix (now biomodal). Dr Mellad holds a PhD in Medicine from the University of Cambridge. Prof Sir Mene Pangalos is former Executive Vice-President, R&D BioPharmaceuticals at AstraZeneca,
EnsiliTech raises £4.5M to stabilize vaccines at room temperature | The Big Deal posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … , but are we doing enough to turn discovery into global opportunity? Our recent Grant Thornton Australia CEO roundtables co-hosted with AusBiotech revealed a clear message: cutting-edge research and talent are here, but fragmented funding and cautious investment are slowing commercialisation. To unlock growth, companies need to engage early with regulators, strengthen IP and manufacturing strategies, and align talent incentives with long-term goals. With the right collaborati … scalable global success. Read the full insights here: https://lnkd.in/gmZgKBGA Grant Thornton Australia 66,718 followers 8mo Pleased to have partnered with AusBiotech to host a dynamic roundtable seminar focused on the pressing issues facing the Biotechnology sector. From funding pathways to talent pipelines and manufacturing hurdles, the conversation was rich with insight and forward-thinking ideas. A big thank you to all who contributed to shaping the future of biotech inn
Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,096.30 +48.70 +1.20% ADVERTIS
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Attending Organisations | Genesis Attending Organisations | Genesis Skip to content Maximising Returns from Life Science Innovation | Thursday 10 December 2026 | London, UK What’s On Conference Programme Awards Company Showcase Exhibition 1-2-1 Partnering at Genesis Sponsor & Exhibit Sponsor & Exhibit Floor Plan & FAQs About Our News Genesis Comms Advisory Panel Attending Companies Conference Collaborators Venue & Accommodation Contact Us Register Here Attending Organisations Who Attended Genesis 2025? Attending Organisations See the organisations that registered for Gene
News & Events - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us News & Events Read the latest updates from MitoRx Therapeutics Show All Press Releases Events Publications In The Media Press Release Posted 9 June, 2026 MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth Read More Press Release Posted 8 June, 2026 MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-target
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Yahoo Finance - Stock Market Live, Quotes, Business & Finance News Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Golf Tennis NFL Athletics Cycling NBA Motorsport … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,096.30 +48.70 +1.20% ADVERTIS
Join Us - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us The team behind the science Join Us Working at MitoRx At MitoRx, we foster a collaborative, science-driven culture in which curiosity and commitment thrive. United by a mission to improve the health and quality of life of patients living with high-risk obesity, we are at an exciting stage in our development and always interested in hearing from experienced people who want to make a difference. For current opportun
Join Us - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us The team behind the science Join Us Working at MitoRx At MitoRx, we foster a collaborative, science-driven culture in which curiosity and commitment thrive. United by a mission to improve the health and quality of life of patients living with high-risk obesity, we are at an exciting stage in our development and always interested in hearing from experienced people who want to make a difference. For current opportun
MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions | The Manila Times --> --> Saturday, June 27, 2026 Today's Paper MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions Sign In New user? Click Here Subscribe Sign In New user? Click Here OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAI
CEO Spotlight: Jon Rees, CEO of MitoRx Therapeutics – UKI2S Home About About us Team When & How we invest Investment Areas Defence & Security Engineering Biology Fusion Knowledge Assets Partner Innovation Space Portfolio Our Impact News Pitch for Investment Pitch for Investment CEO Spotlight: Jon Rees, CEO of MitoRx Therapeutics Published: 20th July 2022 UKI2S > News > CEO Spotlight: Jon Rees, CEO of MitoRx Therapeutics About Jon Rees and MitoRx Therapeutics: • MitoRx is a preclinical research stage biotechnology company developing first-in-class, orally available, mitochon
Jon Rees interview, Open Door Salon Home Newsletter Honored Guests Blog About Us Work With Us ▾ Sponsor & Advertise Reach our audience Be a Guest Share your expertise The Production Suite We produce your content Get the Briefing Home Newsletter Honored Guests Blog About Us Work With Us Sponsor & Advertise Be a Guest The Production Suite Get the Briefing Open Door Salon Home Newsletter About Us Honored Guests Contact Us The Production Suite Jon Rees CEO & Co-Founder, MitoRx Therapeutics | Next-Generation Obesity & Metabolic Health Jon Rees is the chief executive officer an
Onyx @ Jefferies: Jon Rees, CEO, MitoRx Skip to content Dark Search Exclusive CEO Interviews Home Onyx Live News FDA Greenlit Second Opinion Exclusive Interviews Press Releases TLDR Biotech Read Onyx in other publications About Us Live Interviews — Jefferies 2025 Onyx @ Jefferies: Jon Rees, CEO, MitoRx The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection. Dr. Adil Ali November 18, 2025 . 8:43 PM 1 min read Dr. Adil Ali MitoRx Therapeutics are developing first-in-class, mitochondrial-targeted sulfide-don
MitoRx Therapeutics raises GBP 5.5 million pre-Series A round to advance a next generation obesity treatment - Harwell Campus Skip to content Harwell Campus Science and Innovation Research Clusters National Science Facilities Start-ups & Scale-ups Organisations Life Discover News Stories Events Light Project Engine Summit Visit About ^ Our team History Sustainability Press Search for: Workspace Lab space Office space R&D space Vision 2050 Contact Jobs ARC Group Menu Close Search for: Back MitoRx Therapeutics raises GBP 5.5 million pre-Series A round to advance a next generation obesit … lated news View all news Property , Science and innovation Lumen Secures Second Award for Pioneering Neuroinclusive Laboratory Design Lumen, a newly refurbished 17,000 sq ft CL2 fitted laboratory and office building that has set a new industry standard in neuroinclusive lab design, has secured the Innovative Workplace Design Award at the Construction News & Property Week Life Sciences, Tech & Research Clusters Awards. Submitted in conjunction with BondBryan Fairhursts … ering scientific excellence, economic growth and long-term societal impact. The award comes as Harwell celebrates its 80th anniversary, marking eight… Science and innovation , Space and satellites James Webb Space Telescope captures the star-forming clouds of Orion A Located around 1,300 light-years from Earth and situated to the south of Orion’s Belt in the night sky, Orion A is one of the largest and closest molecular clouds to our planet. S
MitoRx appoints new CFO, CMO, and director to a... | Pluang – Crypto, Stocks, Gold & Funds Trade on Pluang One platform for all markets Download Trade on Web Investment Features Fees Safety Learn More Pluang+ EN ID Download Investment Features Fees Safety Academy More Pluang+ ID | EN Trade on Web Home / News Feed / MitoRx appoints new CFO, CMO, and director to advance obesity drug MTRX31 into clinical trials MitoRx appoints new CFO, CMO, and director to advance obesity drug MTRX31 into clinical trials Company Fundamentals 09 Jun 2026 · Mitorx Therapeutics · View Source · Bullish MitoRx The … se. This expansion allows more health plans, TPAs, and self-funded employers to apply e... Market News Bullish · 1 hour ago Identiv's stock drops 30% amid IoT business sale and $40M buyback plan amid legal scrutiny. Identiv is selling its Internet of Things (IoT) business and Thai subsidiary to focus on acquiring software companies. The announcement caused its stock to drop over 30%, hitting a 52-week low of $2.48. A UBS analyst set a $3.10 price target, suggest... Marke … loud-native platfor... Market News Bullish · 3 hours ago Invest & Trade with #1 Award-Winning Investment Super App Trade on Web Download Download Invest US Stocks Crypto ID Stocks New Mutual Funds Gold Options Crypto Futures Features Pluang Web Trading Leverage Auto Invest Pockets USD Yield Pro Features Pluang Cuan 24-Hour Market Aura AI Fees US Stocks Fees Crypto Fees Mutual Funds Fees Gold Fees Other Fees Learn Blog News Academy Campaigns & Promos News Feed Investment C … | V | W | X | Y | Z | © 2026 Pluang. All rights reserved. Pluang is a financial application managed and developed by PT Bumi Santosa Cemerlang, with a mission to provide wider access to various asset classes through easy, secure, and affordable micro-investment products for Indonesians. US Stocks, ETFs, and Options are facilitated by PT PG Berjangka as a Derivatives Broker which is licensed and supervised by the Financial Services Authority of Indonesia (OJK) for financial de … sia (KKI). Mutual Funds are facilitated by PT Sarana Santosa Sejati as a Mutual Fund Securities Selling Agent (APERD) which is licensed and supervised by the Financial Services Authority of Indonesia (OJK). Gold is facilitated by PT Pluang Emas Sejahtera as a Digital Gold Market Maker, which is licensed and supervised by the Commodity Futures Tra
Mitorx Therapeutics raises funds to advance Myo-004 for obesity | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landsca
Knowledge Exchange Awards 2026 | Exeter Innovation Let’s work together Menu About us About us Partnerships in focus IP policy Innovation support Recruit and develop talent Business support Work with an expert Our expertise Data science and AI Future and emerging technologies Health, lifesciences and wellbeing Sustainability and environment Creative economy Defence, security and resilience Responsible business Energy Futures and Engineering Insights and impact Green Futures Solutions Let’s work together Welcome to the Knowledge Exchange Awards The Knowledge Exchange Awards celebrate the b … positive change for communities, businesses, and society. In each of the eight award categories, three projects will be shortlisted following review by a panel of senior University staff and external reviewers. All shortlisted nominees and their partner(s) will be invited to attend the awards ceremony on Thursday 15 October 2026 at the Great Hall, Streatham Campus. A huge thank you to everyone who submitted nominations for this year’s Awards. We received more than 100 … the University of Exeter can help your business. Categories Sustainable Futures Award The Sustainable Futures Award recognises excellence in sustainability, environment and life sciences. Potential innovations can include products, policies, services and community partnerships. Shortlisted Projects: Global Tipping Points Nominated by Dr Andy Richards. Partnered with Potsdam Institute for Climate Impact Research (PIK); WWF UK. KTP with Qube Renewables Ltd No … Hawkes. Partnered with NEOM Nature Reserve. Health, Wellbeing and Life Sciences Award The Health, Wellbeing and Life Sciences Award recognises innovations that lead us to better mental and physical wellbeing. Potential innovations can include products, policies, services and community partnerships . Shortlisted Projects: DOLPHIN_VIVO (Diagnosis of LymPHoma IN VIVO) Nominated by Dr Alex Dudgeon. Partnered with University of Bristol; Gloucestershire Hospitals NHS Foundati … Meertens. Partnered with Ibex Innovations Ltd. Fair, Just and Inclusive Society Award The Fair, Just and Inclusive Society Award recognises innovations towards a more equitable, just and inclusive society. Potential innovations can include products, policies, services, community partnerships, and use of facilities. Shortlisted Projects: Exa
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth Back to All Posts Press Release 9 June 2026 Alison Strutt appointed as Chief Financial Officer, László Tank ó appointed as Consultant Chief Medical Officer, and Sam Fazeli appointed Non-Executi
Onyx Live Skip to content Dark Search Exclusive CEO Interviews Home Onyx Live News FDA Greenlit Second Opinion Exclusive Interviews Press Releases TLDR Biotech Read Onyx in other publications About Us Onyx Live JPM Week San Francisco Jan 12 - 15 Advanced Therapies London Mar 17 - 18 Meeting on the Med Rome Apr 28 - 30 ISCT Dublin Dublin May 6 - 9 BIO Convention San Diego Jun 22 - 25 Jefferies Week London Nov 16 - 19 We hope to see you there! Dr. Adil Ali Editor-in-Chief Dear Onyx readers, we'll be speaking with biotech CEOs across the world this year. If you are a CEO, or you know one working
MitoRx Therapeutics presents additional muscle preservation and liver-fat clearance data in obesity at EASD - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx Therapeutics presents additional muscle preservation and liver-fat clearance data in obesity at EASD Back to All Posts Press Release 16 September 2025 Harwell, Oxford, September 16, 2025, MitoRx Therapeutics Limited (MitoRx), a platform biotech company developing novel mitochondrial-targeted persulfide modifi … han USD 9 million from investors including the UK Innovation & Science Seed Fund managed by Future Planet Capital, the Fink Family Office, Wren Capital, Oxford Technology Management, Empirical Ventures, the Science Angel Syndicate Network, Longevitytech.fund, Panacea Innovation Ventures, as well as angel investors. For more information visit the website at mitorxtherapeutics.com and follow MitoRx on LinkedIn . Contact Us Terms & Conditions Privacy Policy 9400 Garsing
2026 Bio Europe Spring Attendee | LSX Europe You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Life Science Fundraising & Investment 7-8 April 2027 - Main days, Lyon, France 6 April 2027 - Pre-day forums (Life Science Companies only) Home home Biotech expan … s (Guangzhou) Ltd. Choose Paris Region Chordia Therapeutics Inc. Chugai Venture Fund, LLC Chugai Venture Fund, LLC CIC bioGUNE Cilcare Cilcare Claris Ventures Claris Ventures Clayton Biotechnologies, Inc. Clinigen Clinigen Clinigen CNS Pharmaceuticals COCOON BIOSCIENCES Cogitars UK Colab Accelbio Colab Accelbio Colab Accelbio Complement Therapeutics Confo Therapeutics Confo Therapeutics Contera Pharma A/S Contera Pharma A/S CONVEYXO CorriXR Therapeutics CorriXR Therapeutics C … t University Ghent University Ghent University Ghent University GIBF Investment Fund GIBF Investment Fund GIP GENOPOLE GlobalData HealthCare GlobalData HealthCare GlobalData HealthCare GlycoNex GlycoTherapeutics GlycoTherapeutics Gnosis SpA Golgi Neurosciences Golgi Neurosciences Gordian Biotechnology Granzer Regulatory Consulting & Services GmbH Great Bay Bio Limited Greater Geneva Bern area GreenPine Pharma Group Co., Ltd. GreenPine Pharma Group Co., Ltd. Grünenthal Gmb … ents Hyloris Developments HyQure BioTech Co., Ltd HYUNDAI PHARM i&i Biotech Fund I SCSp i&i Biotech Fund I SCSp i&i Prague, s.r.o. i&i Prague, s.r.o. Icosagen Cell Factory OÜ Icosagen Cell Factory OÜ iDEL Therapeutics GmbH iDEL Therapeutics GmbH Idevax IDR Ie Sung International IEUM VALUE CREATOR INC. IGA Technology Services Srl IGES Institut Ignota Labs Ikarovec Limited Ikarovec Limited IMK IC Health Intelligence Immunethep ImmunoDesigners Co., Ltd. ImmunoFor
MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases December 13, 2023 | 4 min read Twitter LinkedIn Facebook Email Print MitoRx Therapeutics announces the final close of its seed extension financing round, with £4m rais … es.” Oliver Sexton, Investment Director at the UK Innovation & Science Seed Fund, said, “MitoRx’s approach to mitochondrial dysfunction will potentially develop a treatment for degenerative diseases that have a hugely harmful impact. Such diseases affect both young and elderly patients who desperately need more treatment options. UKI2S is delighted to continue supporting MitoRx’s development.” MitoRx’s Chief Development Officer, Dr Christine Charman, said, “Interim result … ed by a broad range of investors including the UK Innovation & Science Seed Fund, Wren Capital, Longevitytech.fund, The Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, as well as angel investors. It will be used to fund pre-clinical work in HD, the activation of the company’s first neurodegenerative disease program, and to explore research collaborations and partnerships. The company expects to see preclinical readouts in DMD, HD, an … 4m seed financing from investors including the UK Innovation & Science Seed Fund, Wren Capital, Longevitytech.fund, the Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, as well as angel investors. For more information visit our website at www.mitorxtherapeutics.com and follow us on LinkedIn . About UK Inn
MitoRx Therapeutics Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MitoRx Therapeutics Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity October 10, 2024 | 6 min read Twitter LinkedIn Facebook Email Print OXFORD, United Kingdom, Oct. 10, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a platform biotechnology company d … 4m seed financing from investors including the UK Innovation & Science Seed Fund, the Fink Family Office, Oxford Technology Management, Empirical Ventures, Wren Capital and Longevitytech.fund, as well as angel investors. For more information visit our website at www.mitorxtherapeutics.com and follow us on LinkedIn . About the University of Exeter The University of Exeter is a Russell Group university that combines world-class research with high levels of student satisfact … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth June 9, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Alison Strutt appointed as Chief Financial Officer, László Tank ó appointed as Consultant Chief Medical Officer, and Sam Fazel … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business J … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director January 9, 2025 | 4 min read Twitter LinkedIn Facebook Email Print OXFORD, United Kingdom, Jan. 09, 2025 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a platform biotechnology company … 8m seed financing from investors including the UK Innovation & Science Seed Fund, Wren Capital, Longevitytech.fund, the Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, Panacea Innovation Ventures as well as angel investors. For more information visit our website at mitorxtherapeutics.com and follow us on LinkedIn . Twitter LinkedIn Facebook Email Print Europe People C-suite LATEST Duchenne muscular dystrophy Caprico … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
MitoRx Therapeutics presents exciting new data showing weight loss with muscle preservation for novel small molecule Myo4 targeting obesity - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx Therapeutics presents exciting new data showing weight loss with muscle preservation for novel small molecule Myo4 targeting obesity Back to All Posts Press Release 14 May 2025 Preclinical results presented at ECO 2025 and demonstrate clinical potential of Myo4 compared with cu … eed financing from investors including the UK Innovation &amp; Science Seed Fund, the Fink Family Office, Wren Capital, Oxford Technology Management, Empirical Ventures, the Science Angel Syndicate Network, Panacea Innovation Ventures, Longevitytech.fund, as well as angel investors. For more information visit the website at mitorxtherapeutics.com and follow MitoRx on LinkedIn. Contact Us Terms & Conditions Privacy Policy 9400 Garsington Road, Oxford Business Park Oxf
2022 WINNERS & FINALISTS ⇽ OBN Awards 2022 | BioUK on Glue Up This is a past event. Registration is closed. View other BioUK events. Log In Close Please enter a valid email address e.g. [email protected] Email Address * If you input more than 0 characters your Email Address may not display properly Afghanistan | 🇦🇫 + 93 Aland Islands | 🇦🇽 + 358 Albania | 🇦🇱 + 355 Algeria | 🇩🇿 + 213 American Samoa | 🇦🇸 + 1684 Andorra | 🇦🇩 + 376 Angola | 🇦🇴 + 244 Anguilla | 🇦🇮 + 1264 Antarctica | 🇦🇶 + 672 Antigua and Barbuda | 🇦🇬 + 1268 Argentina | 🇦🇷 + 54 Armenia | 🇦🇲 + 374 Aruba | … NERS & FINALISTS Please click here ​ , for more information about our OBN Award Winners. Best Start-up Biotech Kindly Sponsored by: Partners& ​ Winner: Alevin Therapeutics ​ Finalists: Healome Therapeutics ​ Infinitopes ​ MitoRx Therapeutics Limited ​ Best Start-Up Medtech Kindly Sponsored by: Penningtons Manches Cooper ​ Winner: Microplate Dx ​ Finalists: OxDX Ltd ​ Allos AI ​ Best Emerging B … ​ Finalists: C4X Discovery ​ Touchlight ​ Special Recognition Award Kindly Sponsored by: Milton Park ​ Winner Professor Chris Molloy I n recognition of his advocacy for life science innovators during his tenure as CEO of the Medicines Discovery Catapult, the independent, not-for-profit R&D provider that has reshaped UK drug discovery for patient benefit in the UK. OBN Awards 2022 Winners This is a past event BioUK might have other even … input more than 0 characters your New Password may not display properly Cancel Submit Your password has expired. Change your password to continue. Password must be a minimum of 8 characters and contain at least one upper case letter, one lower case letter, one number , and one special character(!"#$%&'()*+,-./\:;?@[]^_`{|}~=) . Close Password must be a minimum of 8 characters and contain at least one upper case letter, one lower case letter, one number, and one special chara … input more than 0 characters your New Password may not display properly Cancel Submit Email Address Not Found Please go to My Profile and add an email address to continue with this action. Cancel
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
MitoRx Therapeutics Strengthens Leadership with Key Appointments as it Reveals Obesity Programme - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx Therapeutics Strengthens Leadership with Key Appointments as it Reveals Obesity Programme Back to All Posts Press Release 3 October 2024 MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted therapeutics in obesity-related disorders and myopathies announces the appointmen … D and Chair of Audit and Renumeration Committees at Oxford BioDynamics plc, and Fund Advisor for RYSE Asset Management. His expertise will strengthen MitoRx’s efforts as the company advances its mitochondriotropic therapeutic pipeline to address obesity and other degenerative diseases. Dr. David Holbrook, new independent NED at MitoRx, said: “I am excited about the prospects for MitoRx’s mitochondriotropic small molecule platform. I am particularly pleased to join … nt and cardiometabolic diseases. His accolades, including the ADA Harold Rifkin Award for Distinguished International Service, the Diabetes UK Robert Turner Award for Research Impact and the 2024 ADA Banting Medal for Scientific Achievement, underscore his significant contributions. Rury’s scientific insight will be instrumental as MitoRx pioneers new approaches targeting mitochondria in obesity, aiming to develop innovative therapies that address the underlying mechanisms of … 4m seed financing from investors including the UK Innovation & Science Seed Fund, the Fink Family Office, Oxford Technology Management, Empirical Ventures, Wren Capital, Longevitytech.fund, as well as angel investors. MitoRx was spun out of the University of Exeter in Q4 2021. For more information visit our website at www.mitorxtherapeutics.com and follow us on LinkedIn . Contact Us Terms & Conditions Privacy Policy 9400 Garsington Road, Oxford Business Park Oxford O
Obesity Archives - Drug and Device World Skip to content Drug and Device World Home News Pharma News Medical Device News Obesity News Sustainability Latest in Sustainability Sustainability News Company Progress Report and Analysis Expert Interviews AI & Tech Latest in AI and Technology AI and Technology News Expert Interviews Features Latest Features In Conversation With Exclusive Analysis Wellness & Lifestyle Members Only Become A Member Login Manage Membership FAQs Contact Us About the Author Contact Us Advertise Search Obesity From gut resets to microbiome rejuvenation: DDW 2026 hig
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Privacy Policy - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us Privacy Policy The privacy of your personal data is important to us and we are committed to protecting your privacy. This policy sets out how we collect and use your personal data when you interact with us, including any data that you may provide to us when you: visit our website ( https://www.mitorxtherapeutics.com ) (Website); apply for a job with us (whether as an employee, worker or contractor); subscri … curriculum vitae and covering letter, the information you have provided on our application form, including education history, qualifications and employment history; any information you provide to us during the course of your application and any interview process (including any assessments undertaken as part of such process), as well as information obtained from sources other than yourself. We do not collect Special Categories of Personal Data (this includes details about you … iminal record) about you except in limited circumstances. For example, when you apply for a job with us (if you have any particular access requirements or we need to confirm that you do not have a criminal record before offering you a job with us). Your provision of such data would indicate your consent to us using the data for the relevant purpose. Where we are required to do so by law, we have in place an appropriate policy document and safeguards. We (and service providers … st, phone, email or otherwise. This includes personal data you provide when you apply for a job with us, provide us with feedback or contact us. Automated technologies or interactions. As you interact with the Website, we will automatically collect Technical Data about your equipment, browsing actions and patterns. We collect this personal data by using cookies, web beacons, tags, pixels, server logs and other similar technologies. Please see section 14 below for more inform … ghts under data protection laws in relation to your personal data. These rights apply irrespective of where you are resident. You have the right to: Request access to your personal data (commonly known as a subject access request). This enables you to receive a copy of the personal data we hold about you and to check that we are lawfully processi
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director Back to All Posts Press Release 9 January 2025 Oxford, England , 9 th January 2025 – MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted … eed financing from investors including the UK Innovation &amp; Science Seed Fund, Wren Capital, Longevitytech.fund, the Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, Panacea Innovation Ventures as well as angel investors. For more information visit our website at mitorxtherapeutics.com and follow us on LinkedIn . Contact Us Terms & Conditions Privacy Policy 9400 Garsington Road, Oxford Business Park Oxford OX4 2HN, UK Register
Science - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us Restoring mitochondrial health in metabolic disease Science Unmet Need in Obesity Obesity remains a significant global challenge, costing the US healthcare system alone $172bn/year, with over 220 associated comorbidities including cardiovascular disease (US cost: $233bn/year) and diabetes ($413 bn/year). 1 GLP-1 therapies have improved outcomes for many; however, they are associated with low tolerability, loss of
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
MitoRx Therapeutics appoints Xavier Jacq as CSO - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx Therapeutics appoints Xavier Jacq as CSO Back to All Posts Press Release 1 May 2025 Harwell, Oxford, May 1, 2025, MitoRxTherapeutics Limited (MitoRx) , a platform biotech company developing novel mitochondrial-targeted persulfide modifiers, today announces the appointment of Xavier Jacq as Chief Scientific Officer (CSO). Xavier is a world-class scientist with extensiv … in seed financing from investors including the UK Innovation & Science Seed Fund, the Fink Family Office, Wren Capital, Oxford Technology Management, Empirical Ventures, the Science Angel Syndicate Network, Panacea Innovation Ventures, Longevitytech.fund, as well as angel investors. For more information, visit the website at mitorxtherapeutics.com and follow MitoRx on LinkedIn . Contact Us Terms & Conditions Privacy Policy 9400 Garsington Road, Oxford Business Park O
Pipeline - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx’s pipeline is built around our lead asset MTRX31 Pipeline A first-in-class small molecule being developed as a monotherapy for high-risk obesity by restoring healthy mitochondrial metabolism, with potential to be used as a first-line therapy in certain patient populations. Preclinical data for MTRX31 has shown superior magnitude, quality and durability of weight loss compared with tirzepatide in an industr
MitoRx Therapeutics presents data demonstrating restoration of insulin sensitivity, building on its muscle preserving weight loss approach in obesity - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx Therapeutics presents data demonstrating restoration of insulin sensitivity, building on its muscle preserving weight loss approach in obesity Back to All Posts Press Release 23 June 2025 Harwell, Oxford, June23, 2025, MitoRx Therapeutics Limited (MitoRx), a platform … in seed financing from investors including the UK Innovation& Science Seed Fund, the Fink Family Office, Panacea Innovation Ventures, WrenCapital, Oxford Technology Management, Empirical Ventures, the Science AngelSyndicate Network, Longevitytech.fund, as well as angel investors. For moreinformation visit the website at mitorxtherapeutics.com and follow MitoRx on LinkedIn . Contact Us Terms & Conditions Privacy Policy 9400 Garsington Road, Oxford Business Park Oxfor
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
About Us - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx is redefining the treatment paradigm for people living with high-risk obesity About Us At MitoRx, our mission is to support patients with metabolically unhealthy obesity through the development of first-in-class, targeted small-molecule therapies that restore mitochondrial health. Our lead asset, MTRX31, is designed to rebalance carbohydrate and fat oxidation to support healthy metabolism – and has the pot … ink Family Office Oxford Technology Management UK Innovation & Science Seed Fund managed by Future Planet Capital Wren Capital Empirical Ventures Science Angel Syndicate Network Longevitytech.fund Panacea Innovation Capital Contact Us Terms & Conditions Privacy Policy 9400 Garsington Road, Oxford Business Park Oxford OX4 2HN, UK Registered in England and Wales Company No. 13237941 © Copyright 2026 MitoRx Therapeutics Limited - All Rights Reserved .
Science - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us Restoring mitochondrial health in metabolic disease Science Unmet Need in Obesity Obesity remains a significant global challenge, costing the US healthcare system alone $172bn/year, with over 220 associated comorbidities including cardiovascular disease (US cost: $233bn/year) and diabetes ($413 bn/year). 1 GLP-1 therapies have improved outcomes for many; however, they are associated with low tolerability, loss of
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
MitoRx Therapeutics raises GBP 5.5 million pre-series A round to advance a next generation obesity treatment - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx Therapeutics raises GBP 5.5 million pre-series A round to advance a next generation obesity treatment Back to All Posts Press Release 17 November 2025 Harwell Oxford, November 17, 2025, MitoRx Therapeutics Limited (MitoRx), a biotech company developing novel classes of mitochondrial-targeted agents targeting … nk Family Office, OxfordTechnology Management, UK Innovation & Science Seed Fund managed by FuturePlanet Capital, Wren Capital, Empirical Ventures, the Science Angel SyndicateNetwork, Longevitytech.fund, Panacea Innovation Capital, as well as angelinvestors. For more updates or information follow MitoRx on LinkedIn or visit the website at www.mitorxtherapeutics.com. About Oshen Holdings SA Oshen Holdings SA is a European-based family office thatpartners with inventors and
MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us Restoring mitochondrial health in high-risk obesity Our Approach MitoRx is developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity. Our first-in-class small molecule asset, MTRX31, targets the elimination of ectopic fat from affected organs in people with metabolically unhealthy obesity, by restoring mitochondrial health rather than suppressing appetite. This approach
BioSpace - Podcast - Apple Podcasts Buscar Inicio Novedades Lo más escuchado Buscar BioSpace BioSpace 0.0 (0) Ciencias de la vida Cada semana Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development. Episodio más reciente Seguir Episodios hace 1 día The Golden Triangle and the gaps: Rethinking UK biotech In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan … represent those of their organizations. 20 min hace 2 días AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more This year has been partly defined by a return to M&A. In the first quarter of 2026, biopharma spent nearly $47 billion in acquisitions across 19 deals, and this week, AbbVie notched another one for the second quarter, scooping up Apogee Therapeutics and its IL-23 blocker for atopic dermatitis for around $10.9 billion. The deal … for Huntington’s disease and Hunter syndrome, respectively. Both companies will submit for approval of their products—a first submission for uniQure and a resubmission for REGENXBIO—in the third quarter, after the agency, under the leadership of acting commissioner Kyle Diamantas, deemed their current data sufficient. Also at the FDA, a policy memo on the agency’s consideration of Sanofi’s Commissioner’s Priority Review Voucher for type 1 diabetes drug Tzield threw mor … flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed course, setting a decision date for August and later scheduling an advisory committee meeting for June 18. In documents released ahead of that meeting, the FDA and Moderna seem to have reached alignment, though the agency did flag certain data gaps for advisors to review. Biotech IPOs are off the charts—literally. This past month has seen not one but tw
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions | Markets Insider Business Insider My Markets Watchlist Markets News Search Business Strategy Economy Finance Retail Advertising Careers Law Media Real Estate Small Business The Better Work Project Personal Finance Tech Science AI Enterprise Transportation Startups Innovation Markets Stocks Indices Commodities Crypto Currencies ETFs Lifestyle Entertainment Culture Travel Food Health Education Parenting Military & Defe
MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director March 7, 2023 | 4 min read Twitter LinkedIn Facebook Email Print MitoRx Therapeutics announces Christine Charman as Chief Development Officer, David Richardson as Finance Director, and four … “top innovators in the industry”, in 2014 received the “Rita and John Cornforth Award” from the Royal Society of Chemistry, in 2017 and 2018 was voted “Master of the Bench” from the Medicine Maker Power List, and in 2018 was awarded the “Order of the British Empire” in the New Years Honours List. Also joining the board is Prof Dame Kay Davies CBE DBE FRS FMedSci, Dr Lee’s Professor of Anatomy Emeritus at the University of Oxford with an international reputation for work on Du … from a broad range of investors including the UK Innovation & Science Seed Fund, The Fink Family Office, Science Angel Syndicate, Oxford Technology Management, Wren Capital, Longevitytech.fund, as well as angel investors. For more information visit our website at www.mitorxtherapeutics.com and follow us on LinkedIn . Twitter LinkedIn Facebook Email Print People Europe LATEST Duchenne muscular dystrophy Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyo … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
New data backs Myo4 for obesity treatment | News | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Business Webinars Wh
MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases - MitoRx About Overview Our Team Investors Science Overview Unmet Need in Obesity Our Approach Publications Pipeline Overview Partnering News & Events Join Us Contact Us MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases Back to All Posts Press Release 25 April 2022 MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunctio … 221; Oliver Sexton, Investment Director at the UK Innovation & Science Seed Fund, said, “We’re delighted to be supporting MitoRx Therapeutics’ journey in creating innovative therapeutics for degenerative diseases. The company’s platform for reversing mitochondrial dysfunction has great potential to benefit people suffering from both rare and common forms of degenerative disease. ” Professor Hideo Kimura, of Sanyo-Onoda City University, Japan, who is considered the father … ed by a broad range of investors including the UK Innovation & Science Seed Fund, Wren Capital, Longevitytech.fund, The Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, as well as angel investors. The seed financing will be used to fund pre-clinical proof-of-concept platform development and explore research collaborations and partnerships. References (1) January 2021 – Mitochondrial hydrogen sulfide supplementation improves heal … from a broad range of investors including the UK Innovation & Science Seed Fund, Wren Capital, Longevitytech.fund, The Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, as well as angel investors. For more information visit our website at mitorxtherapeutics.com and follow us on LinkedIn . About UK Innovation & Science Seed Fund (UKI2S) UKI2S is a national seed investment fund that nurtures innovative businesses from great … inesses from great UK science to leverage private investment and grow jobs. The Fund is backed by UKRI, Dstl and other public bodies and is independently managed by specialist venture capital firm Midven, part of Future Planet Capital , the impact-led, global venture capital firm built to invest in high growth potential companies from the world’s
MitoRx Therapeutics Strengthens Leadership with Key Appointments as it Reveals Obesity Programme - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MitoRx Therapeutics Strengthens Leadership with Key Appointments as it Reveals Obesity Programme October 3, 2024 | 3 min read Twitter LinkedIn Facebook Email Print OXFORD, United Kingdom, Oct. 03, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mito … D and Chair of Audit and Renumeration Committees at Oxford BioDynamics plc, and Fund Advisor for RYSE Asset Management. His expertise will strengthen MitoRx's efforts as the company advances its mitochondriotropic therapeutic pipeline to address obesity and other degenerative diseases. Dr. David Holbrook, new independent NED at MitoRx, said: "I am excited about the prospects for MitoRx's mitochondriotropic small molecule platform. I am particularly pleased to join the company … nt and cardiometabolic diseases. His accolades, including the ADA Harold Rifkin Award for Distinguished International Service, the Diabetes UK Robert Turner Award for Research Impact and the 2024 ADA Banting Medal for Scientific Achievement, underscore his significant contributions. Rury’s scientific insight will be instrumental as MitoRx pioneers new approaches targeting mitochondria in obesity, aiming to develop innovative therapies that address the underlying mechanisms of … 4m seed financing from investors including the UK Innovation & Science Seed Fund, the Fink Family Office, Oxford Technology Management, Empirical Ventures, Wren Capital, Longevitytech.fund, as well as angel investors. MitoRx was spun out of the University of Exeter in Q4 2021. For more information visit our website at www.mitorxtherapeutics.c
MitoRx Therapeutics Limited | BIO-Europe Spring You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. March 23–25, 2026 FIL (Feira Internacional de Lisboa), Lisbon, Portugal March 31 – April 1, 2026 | Digital Partnering Home home What to expect expand_more Who atte
MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions May 27, 2026 | 2 min read Twitter LinkedIn Facebook Email Print Poster to be presented at ADA 2026 on weight loss induced by MTRX31 … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Weight loss with muscle preservation for novel drug - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Micr